Introduction
Haemolysis is an important interferenc e fac tor that must be c onsidered when making laboratory measurements. Its influenc e should not be ignored. Bec ause of the automation of many analytic al proc esses, inc luding inc reased automation of the pre-analytic al phase, sc reening test material for haemolysis is often lac king. In partic ular samples c ollec ted for c omplete blood testing in nonlaboratory settings have to be transported over longer distanc es bec ause of the inc reasing c onsolidation of laboratories. As a result there is an inc reased risk of haemolysis during storage and/or transportation. Even if haemolysis is not visually detec table, a disc harge of intrac ellular c onstituents into the plasma/serum c an have oc c urred. If the tests are on patients with the haemolytic syndrome ( in-vivo haemolysis) , then differentiating it from in vitro haemolysis, mostly resulting from inappropriate spec imen c ollec tion, is rarely possible. Consequently, analytic al results are often false, fluc tuating between either too high or too low, or giving unexpec ted pathologic al findings, for suc h measurements as potassium, LDH, AST, ac id phosphatase, and/or neurone-spec ific enolase.
The objec tive of this report is to point out the extent of haemolytic interferenc es in laboratory findings, and thereby to dec rease the number of inappropriate spec imen c ollec tions and testing.
H aemolysis
Haemolysis is the release of intrac ellular c omponents from erythroc ytes, thromboc ytes and leukoc ytes into the extrac ellular fluid, i.e. the plasma or serum 1 . Haemolysis is visible as a red c olouration of the plasma or serum after c entrifugation of the sample. Reports in the literature on the c onc entration of free haemoglobin, whic h is visible as a red c oloration in the plasma or serum, varies between 1 0 0 and 3 0 0 mg/L.
Haemolysis c an lead to c hanges of a spec ific parameter in the test material. It is c alled a biologic al influenc e fac tor if the release of the blood-c ell c onstituents took plac e in vivo. In vitro haemolysis is an interferenc e fac tor if it oc c urs after spec imen c ollec tion and c hanges the results of the analytic al proc ess 2 .
Thromboc ytolysis and granuloc ytolysis c an also influenc e test results without visual haemolysis 3 . On examination of the c oagulation proc ess it is evident that thromboc ytolysis is responsible for the higher c onc entration of a number of intrac ellular c omponents in serum c ompared to the plasma. An intravasc ular destruc tion of leukoc ytes c an lead to inc reased lysozyme levels in myeloid and monoc ytic leukaemia's.
Causes of H aemolysis
Visual pre-analytic al inspec tion of c entrifuged blood samples for haemolysis is the reason for rejec tion in 6 0 % of the rejec ted samples. In a medic al study 4 , 3 .3 % of the spec imens that were sent to the laboratory for c linic al c hemic al investigation were haemolysed. When examining the reason, in only 3 .2 % of haemolysed samples was in vivo haemolysis the c ause. • strong aspiration, particularly while puncturing superficial veins. Aspiration using thin needles should cause less haemolysis than use of large ones because the flow-rate, flow speed and turbulence is less, and as a result haemolysis is reported to be lower 5 .
• partial obstruction of a venous or arterial catheter. As a result there is a more intense aspiration if the sample is collected with a syringe.
• specimen collection with a syringe and subsequent splitting of the sample into several tubes.
In vitro-haemolysis 1
Several fac tors c ausing in vitro haemolysis are enc ountered during the venipunc ture proc edure ( Table 1 ) . Further possibilities for inac c urac ies are presented in Table 2 .
In vivo-haemolysis
In-vivo haemolysis is c aused by antibodies, bioc hemic ally through medic ations, by toxic substanc es, through hereditary fac tors ( e.g. haemoglobinopathies) , through enzyme defec ts ( ac holuric jaundic e) or by infec tions ( e.g. malaria) . When suspec ting in vivo haemolysis the plasma should be c hec ked to exc lude the possibility of additional in vitro haemolysis1 c aused by the c oagulation proc ess.
H aemolysis detection
Haemolysis is visible in non-ic teric samples as a red c oloration of serum and plasma. It is visible to the eye if the c onc entration of free haemoglobin is above 3 0 0 mg/L. Quantitation of free haemoglobin below this c onc entration is obtained immuno-nephelometric ally 7 or spec trophotometric ally using a bic hromatic method ( e.g. ACA) . The upper referenc e limit for free haemoglobin in plasma is 2 0 mg/L; for serum it is 5 0 mg/L.
Plasma/Serum changes through H aemolysis
Released c omponents of blood c ells, whose intrac ellular c onc entrations are more than 1 0 x higher than their extrac ellular c onc entrations, might inc rease the plasma/ serum c onc entrations of these c omponents signific antly through in vivo and in vitro haemolysis. In partic ular potassium, LD and AST levels bec ome elevated. Measured c omponents whose levels are higher in serum than in plasma c ome from thromboc ytes, i.e. potassium, neuronespec ific enolase and ac id phosphatase. Indic ators of haemolysis are presented in Table 3 .
Differentiation of in vivo-and in vitrohaemolysis
Even if in vitro haemolysis oc c urs more frequent than in vivo, the latter is of greater c linic al importanc e bec ause of its pathologic al origin, and bec ause the parameters influenc ed by haemolysis are relevant for diagnosis, follow-up and therapeutic monitoring of the diseases. In c ases of suspec ted in vivo haemolysis sample rejec tion is c onsidered malprac tic e. For this reason a differentiation ( in vivo/in vitro) has to be c arried out on every haemolytic sample.
In vivo released haemoglobin is bound to haptoglobin and transported into the retic uloendothelial system ( RES) , mostly to the spleen. Free haemoglobin c an only be measured in plasma if the haptoglobin transport c apac ity is exc eeded. Then haptoglobin c annot be measured using immunonephelometric or immunoturbidimetric methods. Haptoglobin c onc entrations in the referenc e range c an be measured if there is a simultaneous ac ute-phase response ( CRP inc reased) or in patients with hypersplenism. Inc rease in haptoglobin c onc entration and free haemoglobin has been reported in patients with plasmac ytoma 8 .
In patients having the HELLP-syndrome the c onc entration of haptoglobin in plasma c an be normal on diagnosis. However, it will dec rease within the following 1 0 days 1 0 .
When suspec ting a haemolytic syndrome the dec rease of haptoglobin and the rise in LD, indirec t bilirubin and the retic uloc yte index depend on the degree of haemolysis. In extensive haemolysis, c hanges in LD, indirec t bilirubin and haptoglobin will oc c ur within 2 4 hours. However, a rise in the retic uloc yte index oc c urs 2 days later, at the earliest. An inc rease in indirec t bilirubin is only measurable if the haemolysis rate ( usually 0 ,8 %) rises above 5 %. In intravasal haemolysis a rise in LD ( whic h c auses a c hange in the LD elec trophoresis pattern partic ularly of LD1 and LD2 ) c an only be measured if the retic uloc yte index is above 1 0 %. In a subjec t with an LD ac tivity of 1 6 5 U/L and an in vitro haemolysis of 8 0 0 mg the serum haemoglobin c aused a 5 8 % inc rease in LD ac tivity /1 0 /. Massive Criteria to distinguish in vivo and in vitro haemolysis are shown in Table 4 .
H aemolysis as an interference factor
Constituents that have been released from blood c ells and that subsequently have been mixed with the extrac ellular fluid c an c hange the plasma/serum c onc entration or ac tivity of c ertain c omponents for the following reasons:
Inc reased or dec reased values bec ause of a c onc entration gradient between the c ells and the plasma.
Constituents released from blood c ells c an interfere with the c hemic al reac tions used to analyse for plasma/serum c omponents ( e.g. the peroxidase ac tivity of haemoglobin affec ts bilirubin measurement and released adenylkinase the measurement of CK) .
Haemoglobin in the sample c an interfere with c hemic al reac tions bec ause it c hanges the molar extinc tion c oeffic ient of the substrate or reac tion produc t to be measured.
Hemoglobin absorbs light very strongly at 4 1 5 nm ( Soret wave) . Haemolysis therefore inc reases absorption in this wavelength range and c auses an apparent inc rease in the c onc entration of analytes measured in this range. Interferenc es of c linic al c hemic al tests through haemolysis have been pub-lished many times 1 2 -1 4 . A list of frequently interfering parameters is presented in Table 5 .
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Table 4: Different types of haemolysis
In vitro-haemolysis parallel inc rease of haemoglobin ( red c oloration of plasma/serum) , potassium, LD and AST respec tively, but haptoglobin and retic uloc yte-index remains normal, unforeseen inc rease in potassium, but no red c oloration of plasma/serum, LD in referenc e range, i.e. if whole blood is stored for several days,
In vivo-haemolysis parallel inc rease in haemoglobin ( red c oloration of plasma/serum) and LD but no parallel inc rease in potassium, no red c oloration of plasma/serum, but dec rease in haptoglobin and potential inc rease in LD, indirec t bilirubin and/or retic uloc yte-index, respec tively, serum/plasma without red c oloration, but inc rease in LD, potassium and ac id phosphatase. In plasma no inc rease of these parameters ( i.e. has been notic ed in thromboc ytosis) . 
Serum proteinelectrophoresis
Haemoglobin-haptoglobin-complexes move between the α2-and ß-Globulin fractions. Free haemoglobin migrates as a diffuse reddish band in the ß-globulin fraction.
Immunoassays
Immunoassays are evaluated by diagnostic kit manufacturers for interferences to haemolysis in the same way as other clinical chemistry tests. However, the manufacturers often only add haemoglobin (mostly human methemoglobin is used) to samples. W hen suspecting an haemolysis interference factor of an immunoassay haemoglobin should not be confused with haemolysis. Blood cells contain components other than haemoglobin that can hamper immunoassays. Therefore, it is very important to ask the product manufacturer how haemolysis testing was performed. 
